We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMA.
- Authors
Westin, J.; Jacobson, C. A.; Chavez, J. C.; Sureda, A.; Morschhauser, F.; Glaß, B.; Dickinson, M.; Davies, A.; Flinn, I. W.; Maloney, D. G.; Chamuleau, M.; Tees, M.; Xue, A.; Shahani, S.; Nikolajeva, O.; Kang, J.; Kaplan, A.; Schupp, M.; Miao, H.; Rich, E. S.
- Abstract
B Methods: b The Phase 3 trial design will enroll 300 adult patients with high-risk, histologically confirmed LBCL based on the 2016 WHO classification, including diffuse large B-cell lymphoma, HGBL, and transformed follicular or marginal zone lymphoma (Swerdlow SH, et al. I Blood i . 2016). B Introduction: b The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) and DA-EPOCH-R (dose-adjusted etoposide [DA-E]), have poor prognoses. ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA.
- Subjects
DIFFUSE large B-cell lymphomas; NURSING consultants; MUCOSA-associated lymphoid tissue lymphoma; LYMPHOMAS; CYTOKINE release syndrome
- Publication
Hematological Oncology, 2023, Vol 41, p171
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_T06